EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. (Q35008440)

5 August 2017

title

EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. (English)

1 reference

5 August 2017

Zuzana Walker

9

0 references

Flavio Nobili

object named as

Flavio Nobili

8

0 references

Klaus Tatsch

3

object named as

Klaus Tatsch

1 reference

5 August 2017

10

Koen Van Laere

1 reference

5 August 2017

Jacques Darcourt

1

1 reference

5 August 2017

Jan Booij

2

1 reference

5 August 2017

Andrea Varrone

4

1 reference

5 August 2017

Thierry Vander Borght

5

1 reference

5 August 2017

Ozlem L Kapucu

6

1 reference

5 August 2017

Kjell Någren

7

1 reference

5 August 2017

publication date

1 February 2010

1 reference

5 August 2017

number of pages

8

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

5 August 2017

volume

37

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

443-450

1 reference

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease

5 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007/S00259-009-1267-X

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S00259-009-1267-X

The dosimetry of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S00259-009-1267-X

Role of DAT-SPECT in the diagnostic work up of parkinsonism

21 January 2018

1 reference

12 December 2020

Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT.

1 reference

12 December 2020

European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.

1 reference

12 December 2020

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake

1 reference

12 December 2020

Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects

1 reference

12 December 2020

Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT.

1 reference

12 December 2020

[Clinical applications of single photon emission tomography in neuromedicine. 1. Neuro-oncology, epilepsy, movement disorders, cerebrovascular disease]

1 reference

12 December 2020

The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation

1 reference

12 December 2020

Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs

1 reference

12 December 2020

Decreased dopamine transporter availability in male smokers -- a dual isotope SPECT study

1 reference

12 December 2020

Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images

1 reference

12 December 2020

Levodopa and the progression of Parkinson's disease

1 reference

12 December 2020

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease

1 reference

12 December 2020

Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact

1 reference

12 December 2020

One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.

1 reference

12 December 2020

Influence of high-energy photons on the spectrum of iodine-123 with low- and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice

1 reference

12 December 2020

Imaging of the dopaminergic system in parkinsonism with SPET.

1 reference

12 December 2020

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group

1 reference

12 December 2020

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study

1 reference

12 December 2020

Brain radioligands--state of the art and new trends

1 reference

12 December 2020

Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes

1 reference

12 December 2020

The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease

1 reference

12 December 2020

Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm.

1 reference

12 December 2020

Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.

1 reference

12 December 2020

Human biodistribution and dosimetry of [ 123 I]FP-CIT: a potent radioligand for imaging of dopamine transporters

1 reference

12 December 2020

Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.

1 reference

12 December 2020

Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies?

1 reference

12 December 2020

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

1 reference

12 December 2020

10.1007/S00259-009-1267-X

Identifiers

DOI

1 reference

5 August 2017

1 reference